FRα is an attractive TAA since about 70% of EOC and breast cancer patients showed measurable immune responses against FRα [169], and, due to its highly restricted distribution and overexpression in EOC, FRα is a suitable candidate for cancer immunotherapy. This evidence concerns the gene FOLR1 and breast cancer.